Latest Conference Articles

Gene profiling assays can accurately and reproducibly assist decision making for patients with hormone receptor-positive breast cancer, with the ultimate goal of improving outcomes or avoiding toxicity.

Mark E. Robson, MD, discusses the potential utility of tucatinib in the treatment of patients with HER2-positive breast cancer.

The release of new evidence that CDK4/6 inhibition results in survival gains for patients with hormone receptor–positive, HER2-negative metastatic breast cancer marks a new milestone for the therapeutic approach and may help set the stage for expanding use of these agents into earlier clinical settings.

Given the solid correlation between the risk of locoregional recurrence (LRR) and distant recurrence, several investigators have examined whether genomic assays that predict risk of distant recurrence can also predict risk of LRR.

There are clear biomarkers available to guide treatment decisions in the second-line setting for patients with advanced hepatocellular carcinoma, Lipika Goyal, MD, Mphil, said during a presentation at the 2020 HCC-TAG Conference.

By 2025, Anthony El-Khoueiry, MD, expects to see a larger menu of approved drugs and drug combinations for the treatment of advanced hepatocellular carcinoma, better use of molecular and immune signatures to guide treatment decisions, and, possibly, the chance to cure intermediate- and advanced-stage disease.

Michael R. Charlton, MD, MBBS, discusses the evolution of hepatocellular carcinoma treatment.

Riad Salem, MD, discusses the utility of locoregional therapy versus systemic therapy in the treatment of patients with hepatocellular carcinoma.

Amit G. Singal, MD, discusses the importance of early diagnosis for patients with hepatocellular carcinoma.

The diagnosis and management of smoldering multiple myeloma is an area of tremendous focused research and change over the past decade, with trials yielding intriguing findings that have the potential to change practice.

Following a series of negative phase III single-agent trials in hepatocellular carcinoma, investigators are finding better results with immunotherapy combination regimens.

Clinical evidence shows that patients with hepatocellular carcinoma who receive care that incorporates multiple providers from a variety disciplines leads to better results.

Anjana Pillai, MD, reflects on the first annual HCC-TAG Conference, her journey into treating patients with liver cancer, and remaining challenges in the paradigm

Noopur Raje, MD, discusses the investigational CAR T-cell therapies and strategies in the multiple myeloma pipeline.

Corey S. Cutler, MD, MPH, discusses how physicians can optimize treatment management in patients with both acute and chronic graft-versus-host-disease.

Jerald P. Radich, MD, discusses how the role of minimal residual disease (MRD) has evolved recently in clinical trials of hematologic malignancies.

Yujin Hoshida, MD, PhD, discusses molecular subtyping in hepatocellular carcinoma.

David J. Pinato, MD, PhD, discusses the lack of biomarkers in hepatocellular carcinoma.

Richard S. Finn, MD, reflects on data from the phase III REFLECT, RESORCE, CELESTIAL, and REACH-2 trials in hepatocellular carcinoma.

At the 24th Annual International Congress on Hematologic Malignancies®, Sonali M. Smith, MD, detailed the critical clinical trial findings currently informing treatment selection in the frontline indolent non-Hodgkin lymphoma paradigm.

David J. Pinato, MD, PhD, highlights the clinical and biological challenges in identifying biomarkers in hepatocellular carcinoma, and the potential introduction of biomarkers in the future.

A number of therapeutic options have become available in the frontline setting for patients with chronic lymphocytic leukemia, most recently the second-generation BTK inhibitor acalabrutinib.

Sonali M. Smith, MD, discusses the prognosis of patients with indolent non-Hodgkin lymphomas.

With the main toxicities associated with CAR T-cell therapy being cytokine release syndrome and neurotoxicity, a multidisciplinary approach is vital to providing inclusive care to patients receiving this type of treatment.

Jorge E. Cortes, MD, shares his experience with tyrosine kinase inhibitors as treatment of patients with chronic myeloid leukemia.

Neehar Parikh, MD, discusses the importance of multidisciplinary care in the treatment of patients with hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, discusses ways to optimize treatment selection for patients with hepatocellular carcinoma.

Findings from the phase III IMbrave 150 trial represented the first time a treatment outperformed sorafenib for overall survival and progression-free survival in patients with unresectable hepatocellular carcinoma (HCC), and the HCC world was understandably excited, said Ghassan K. Abou-Alfa, MD.

Newly approved and investigational agents are joining ruxolitinib for the treatment of myelofibrosis and may provide options for patients who progress or become intolerant to frontline JAK inhibitors.

Sagar Lonial, MD, FACP, discusses how the treatment landscape has evolved for patients with smoldering multiple myeloma.